A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Breast Cancer
Interventions: DRUG: faslodex 500mg|DRUG: arimidex 1mg|DRUG: faslodex dummy|DRUG: arimidex dummy
Sponsor: AstraZeneca